This dataset counts 24,746 published records matching core siRNA design terms such as siRNA duplex, seed region, chemical modification pattern and strand selection, spanning 2015 through mid-2026. That figure covers publications, not granted patents specifically, and includes multiple documents belonging to the same underlying family in some cases. Because publication lags filing by roughly eighteen months, the true number of filings from 2025 onward is understated in any count taken today.

The ranking covers 100 companies at the family level, led by a major RNA-therapeutics pharmaceutical company with 2,471 records, well ahead of the fifth-place filer at 725. Several research universities and institutes also appear prominently and frequently co-file with one another, reflecting shared laboratories and licensing arrangements. The five most active assignees together account for 25.1% of all 24,746 records in scope, and the ten most active for 35.1%, leaving most of the corpus spread across a long tail of smaller filers.

Filing peaked at 1,320 records in 2022 and eased to 1,019 by 2024, an 8% decline across that three-year span — a plateau rather than a sharp retreat. Figures for 2025 and 2026 appear much lower, but that reflects publication lag, since disclosures typically take about eighteen months to appear in the record, not a genuine drop in research activity. Momentum at several individual leading assignees has fallen more sharply year-on-year, which is worth investigating case by case before drawing conclusions about the field overall.